We have established a fund to assist patients with travel and travel-related expenses related to the ATTAC-II cell therapy clinical trial.
In recognition of potential cost burdens to enroll and participate in clinical trials, Immunomic Therapeutics established a fund to reduce the costs of travel for patients who meet the enrollment criteria of the ongoing ATTAC-II clinical study. This trial is enrolling patients with newly-diagnosed glioblastoma at two trial sites: one at the University of Florida in Gainesville, FL, and the other at Duke University Medical Center in Durham, North Carolina. The ATTAC-II clinical trial (NCT02465268) is testing a vaccine therapy given alongside radiotherapy and standard of care chemotherapy.
The study chair is Dr. Duane Mitchell, MD, PhD, University of Florida. Dr. Mitchell’s prior work on this vaccine therapy has been published in Nature and Cancer Cell.
- Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
- Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
The ATTAC-II Trial information can be found at ClinicalTrials.gov (NCT02465268) and is titled, “A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma”.
Trial Enrollment and the Travel Fund
The travel fund is for enrolled patients living 100 miles away from a trial site. Patients who meet that criteria will receive travel sponsorship for the duration of their participation in the clinical trial. The travel fund provides reimbursement for travel arrangements, including roundtrip coach flights for the patient and up to 1 caregiver, hotel accommodations for each visit (1-2 nights, depending on treatment) and car rental for each visit.